The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Anaplastic Thyroid Cancer: A Review of Epidemiology, Pathogenesis, and Treatment
Open accessAbstract
Anaplastic thyroid cancer (ATC) is an uncommon malignancy of the thyroid. Only 1-2% of thyroid cancers are anaplastic, but the disease contributes to 14–50% of the mortality with a median survival of 3 to 5 months. Most patients diagnosed with this disease are 65 years of age or older. The incidence of anaplastic thyroid cancer is decreasing worldwide. Most patients present with a rapidly growing neck mass, dysphagia, or voice change. We performed a comprehensive literature search using PubMed focusing on the treatment of anaplastic thyroid cancer including historical review of treatment and outcomes and investigations of new agents and approaches. A total of sixteen chart review and retrospective studies and eleven prospective studies and/or clinical trials were reviewed. The current standard therapeutic approach is to consider the disease as systemic at time of diagnosis and pursue combined modality therapy incorporating cytoreductive surgical resection where feasible and/or chemoradiation either concurrently or sequentially. Doxorubicin is the most commonly used agent, with a response rate of 22%. Several new agents are currently under investigation. Referral of patients for participation in clinical trials is needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Increasing Incidence of Thyroid Cancer in the United States, 1973-2002
Davies, L., & Welch, H. G. (2006) · JAMA · doi:10.1001/jama.295.18.2164 · Cited by 3,369
Hundahl, S. A., Fleming, I. D., Fremgen, A. M., & Menck, H. R. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19981215)83:12<2638::aid-cncr31>3.0.co;2-1 · Cited by 1,836
Gilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4
Pettit, G. R., Singh, S. B., Hamel, E., Lin, C. M., Alberts, D. S., & Garcia-Kendal, D. (1989) · Experientia · doi:10.1007/bf01954881 · Cited by 786
Inai, T., Mancuso, M., Hashizume, H., Baffert, F., Haskell, A., Baluk, P., Hu-Lowe, D. D., Shalinsky, D. R., Thurston, G., Yancopoulos, G. D., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63273-7 · Cited by 757
Phase II Trial of Sorafenib in Advanced Thyroid Cancer
Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3279 · Cited by 680
Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors
Kebebew, E., Greenspan, F. S., Clark, O. H., Woeber, K. A., & McMillan, A. (2005) · Cancer · doi:10.1002/cncr.20936 · Cited by 666
Cohen, E. E. W., Rosen, L. S., Vokes, E. E., Kies, M. S., Forastiere, A. A., Worden, F. P., Kane, M. A., Sherman, E., Kim, S., Bycott, P., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9566 · Cited by 623
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., & Chaplin, D. J. (1997) · PubMed · Cited by 622
Hundahl, S. A., Cady, B., Cunningham, M. P., Mazzaferri, E., McKee, R. F., Rosai, J., Shah, J. P., Fremgen, A. M., Stewart, A. K., H�lzer, S., et al. (2000) · Cancer · doi:10.1002/1097-0142(20000701)89:1<202::aid-cncr27>3.0.co;2-a · Cited by 514
Anaplastic carcinoma of the thyroid: A clinicopathologic study of 121 cases
Venkatesh, Y. S. S., Ordonez, N. G., Schultz, P. N., Hickey, R. C., Goepfert, H., & Samaan, N. A. (1990) · Cancer · doi:10.1002/1097-0142(19900715)66:2<321::aid-cncr2820660221>3.0.co;2-a · Cited by 486
Anaplastic thyroid carcinoma: A 50-year experience at a single institution
McIver, B., HAY, I. D., Giuffrida, D., et al. (2001) · Surgery · doi:10.1067/msy.2001.118266 · Cited by 484
Shimaoka, K., Schoenfeld, D. A., Dewys, W. D., Creech, R. H., & Deconti, R. (1985) · Cancer · doi:10.1002/1097-0142(19851101)56:9<2155::aid-cncr2820560903>3.0.co;2-e · Cited by 464
Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches
Are, C., & Shaha, A. R. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.05.042 · Cited by 440
Ain, K. B., Egorin, M. J., DeSimone, P. A., & Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group* (2000) · Thyroid · doi:10.1089/thy.2000.10.587 · Cited by 295
Haigh, P. I., Ituarte, P. H. G., Wu, H. S., Treseler, P. A., Posner, M. D., Quivey, J. M., Duh, Q. Y., & Clark, O. H. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12<2335::aid-cncr1266>3.0.co;2-1 · Cited by 292
Vincent, L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24586 · Cited by 242
Anaplastic carcinoma of the thyroid: A 24‐year experience
Tan, R. K. L., Finley, R. K., Driscoll, D., Bakamjian, V. Y., Hicks, W. L., & Shedd, D. P. (1995) · Head & Neck · doi:10.1002/hed.2880170109 · Cited by 237
Tennvall, J., Lundell, G., Wahlberg, P., Bergenfelz, A., Grimelius, L., Åkerman, M., Hjelm Skog, A.-L., & Wallin, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600361 · Cited by 235
Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy
Kim, J. H., & Leeper, R. D. (1987) · Cancer · doi:10.1002/1097-0142(19871115)60:10<2372::aid-cncr2820601004>3.0.co;2-1 · Cited by 232
De Crevoisier, R., Baudin, E., Bachelot, A., Leboulleux, S., Travagli, J.-P., Caillou, B., & Schlumberger, M. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.032 · Cited by 221
The pediatric cancer quality of life inventory-32 (PCQL-32): I. Reliability and validity
Varni, J. W., Katz, E. R., Seid, M., Quiggins, D. J. L., & Friedman-Bender, A. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980315)82:6<1146::aid-cncr20>3.0.co;2-5 · Cited by 217
Anaplastic carcinoma of the thyroid
Lo, C.-Y., Lam, K.-Y., & Wan, K.-Y. (1999) · The American Journal of Surgery · doi:10.1016/s0002-9610(99)00052-5 · Cited by 208
Pathak, M. K., & Yi, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3391 · Cited by 190
Lam, K.-Y., Lo, C.-Y., Chan, K.-W., & Wan, K.-Y. (2000) · Annals of Surgery · doi:10.1097/00000658-200003000-00005 · Cited by 182
Mooney, C. J., Nagaiah, G., Fu, P., Wasman, J. K., Cooney, M. M., Savvides, P. S., Bokar, J. A., Dowlati, A., Wang, D., Agarwala, S. S., et al. (2009) · Thyroid · doi:10.1089/thy.2008.0321 · Cited by 180
Self-citationClinical multidrug resistance in cancer: A multifactorial problem
Lehnert, M. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00069-x · Cited by 176
Schiff, B. A., McMurphy, A. B., Jasser, S. A., Younes, M. N., Doan, D., Yigitbasi, O. G., Kim, S., Zhou, G., Mandal, M., Bekele, B. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0690 · Cited by 169
Furuya, F., Shimura, H., Suzuki, H., Taki, K., Ohta, K., Haraguchi, K., Onaya, T., Endo, T., & Kobayashi, T. (2004) · Endocrinology · doi:10.1210/en.2003-1258 · Cited by 157
Yu, G., Li, J. C.-L., Branovan, D. I., McCormick, S. A., & Schantz, S. P. (2010) · Thyroid · doi:10.1089/thy.2008.0281 · Cited by 149
Kim, S., Yazici, Y. D., Calzada, G., Wang, Z.-Y., Younes, M. N., Jasser, S. A., El‐Naggar, A. K., & Myers, J. N. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0595 · Cited by 138
Multimodality treatment for anaplastic thyroid carcinoma – Treatment outcome in 75 patients
Swaak‐Kragten, A. T., de Wilt, J. H. W., Schmitz, P. I. M., Bontenbal, M., & Levendag, P. C. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.02.016 · Cited by 127
Catalano, M. G., Fortunati, N., Pugliese, M., Poli, R., Bosco, O., Mastrocola, R., Aragno, M., & Boccuzzi, G. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06970 · Cited by 121
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
Murata, R., Siemann, D. W., Overgaard, J., & Horsman, M. R. (2001) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(01)00384-x · Cited by 109
Kim, S., Prichard, C. N., Younes, M. N., Yazici, Y. D., Jasser, S. A., Bekele, B. N., & Myers, J. N. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1325 · Cited by 96
Manumycin enhances the cytotoxic effect of paclitaxel on anaplastic thyroid carcinoma cells.
Yeung, S. J., Xu, G., Pan, J., Christgen, M., & Bamiagis, A. (2000) · PubMed · Cited by 92
Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma
Wong, C. S., Dyk, J. V., & Simpson, W. J. (1991) · Radiotherapy and Oncology · doi:10.1016/0167-8140(91)90105-p · Cited by 88
Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer
Mitsiades, C. S., Poulaki, V., McMullan, C. J., Negri, J. M., Fanourakis, G., Goudopoulou, A., Richon, V. M., Marks, P. A., & Mitsiades, N. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0776 · Cited by 88
The Selective Tyrosine Kinase Inhibitor, STI571, Inhibits Growth of Anaplastic Thyroid Cancer Cells
Podtcheko, A., Ohtsuru, A., Tsuda, S., Namba, H., Saenko, V., Nakashima, M., Mitsutake, N., Kanda, S., Kurebayashi, J., & Yamashita, S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021230 · Cited by 82
Grosios, K., Loadman, P. M., Swaine, D. J., et al. (2000) · PubMed · Cited by 81
Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788
Kim, S., Schiff, B. A., Yigitbasi, O. G., Doan, D., Jasser, S. A., Bekele, B. N., Mandal, M., & Myers, J. N. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0293 · Cited by 68
Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells
Kurebayashi, J., Okubo, S., Yamamoto, Y., Ikeda, M., Tanaka, K., Otsuki, T., & Sonoo, H. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0185-x · Cited by 54
Burke, J. P., HAY, I. D., Dignan, F. L., Goellner, J. R., Achenbach, S. J., Oberg, A. L., & Melton, L. J. (2005) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61529-2 · Cited by 51
Imanishi, R., Ohtsuru, A., Iwamatsu, M., Iioka, T., Namba, H., Seto, S., Yano, K., & Yamashita, S. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020877 · Cited by 48
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma
Voigt, W., Kegel, T., Weiss, M., Mueller, T., Simon, H., & Schmoll, H. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0673-0 · Cited by 41
Lower Incidence of Anaplastic Carcinoma After Higher Iodination of Salt in Slovenia
Bešič, N., Hočevar, M., & Žgajnar, J. (2010) · Thyroid · doi:10.1089/thy.2009.0404 · Cited by 35
Alfano, R. W., Leppla, S. H., Liu, S., Bugge, T. H., Ortiz, J. M., Lairmore, T. C., Duesbery, N. S., Mitchell, I. C., Nwariaku, F. E., & Frankel, A. E. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0694 · Cited by 31
Podtcheko, A., Ohtsuru, A., Namba, H., Saenko, V., Starenki, D., Palona, I., Sedliarou, I., Rogounovitch, T., & Yamashita, S. (2006) · Radiation Research · doi:10.1667/rr3466.1 · Cited by 26
Anaplastic thyroid carcinoma: Long‐term survival after radical surgery
Goldman, J. M., Goren, E. N., Cohen, M. H., Webber, B. L., Brennan, M. F., & ROBBINS, J. J. (1980) · Journal of Surgical Oncology · doi:10.1002/jso.2930140413 · Cited by 22
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Filetti, S., Durante, C., Hartl, D., Leboulleux, S., Locati, L. D., Newbold, K., Papotti, M. G., & Berruti, A. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz400 · Cited by 1,200
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Haddad, R. I., Bischoff, L., Ball, D., Bernet, V., Blomain, E., Busaidy, N. L., Campbell, M., Dickson, P., Duh, Q.-Y., Ehya, H., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0040 · Cited by 510
The role of tumour-stromal interactions in modifying drug response: challenges and opportunities
McMillin, D. W., Negri, J. M., & Mitsiades, C. S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3870 · Cited by 474
Anaplastic lymphoma kinase (ALK): Structure, oncogenic activation, and pharmacological inhibition
Roskoski, R. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.11.007 · Cited by 303
Metadata
- Authors
- Nagaiah, G., Hossain, A., Mooney, C. J., Parmentier, J., & Remick, S. C.
- Venue
- Journal of Oncology
- Publisher
- Wiley
- Published
- 2011
- Volume
- 2011
- Pages
- 1-13
- ISSN
- 1687-8450 (ISSN-L)
- 1687-8469
- OpenAlex
- W2044715980
- Cited by
- 317
- References
- 50
- FWCI
- 12.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.